Open AccessProtease Inhibitors or NNRTIs as First-Line HIV-1 Treatment in West Africa (PIONA): A Randomized Controlled Trial
Author(s) -
Sanne Jespersen,
Bo Langhoff Hønge,
Henrik Krarup,
Patrik Medstrand,
Allan Sørensen,
Candida Medina,
David Te,
Faustino Gomes Correira,
Christian Erikstrup,
Lars Østergaard,
Christian Wejse,
Alex Lund Laursen
Publication year - 2018
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0000000000001820
Subject(s) - efavirenz , lopinavir , nevirapine , ritonavir , medicine , tolerability , hazard ratio , context (archaeology) , randomized controlled trial , reverse transcriptase inhibitor , clinical endpoint , darunavir , viral load , confidence interval , adverse effect , virology , human immunodeficiency virus (hiv) , biology , antiretroviral therapy , paleontology
Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are recommended as part of first-line treatment for HIV-1 in Africa. However, NNRTI-based regimens are more prone to resistance development than protease inhibitors (PIs) in a context in which drug interruptions are frequent. The aim of this study was to compare the efficacy and tolerability of NNRTIs with PIs in HIV-1-infected patients in Guinea-Bissau.